18FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report. (11th October 2011)

• Record Type: Journal Article
• Authors: Otsuka, Kazunori; Takahashi, Masahiro; Nanjo, Hiroshi; Miyazawa, Hideaki; Iida, Masatake; Abe, Yuki; Jin, Mario; Onishi, Hirohide; Hashimoto, Manabu; Yamamoto, Yuzo; Shibata, Hiroyuki
• Other Names: Chichareon S. B. Academic Editor.; Goodman A. Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2011(2011)
• Publication Date: 2011-10-11
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2011/638794
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an effective drug that can be used as a first-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however, in some types of GISTs, it is impossible to obtain a sufficient amount of specimen for diagnosis. An inoperable or marginally resectable GIST in a 79-year-old female was difficult to be diagnosed at a molecular pathological level, and hence, exploratory treatment was initiated using imatinib combined with 18 FDG-PET evaluation at 1-month intervals. PET imaging indicated a positive response, and so we continued imatinib treatment in an NAC setting for 4 months. As a result, curative resection of the entire tumor was successfully performed with organ preservation and minimally invasive surgery. 18 FDG-PET evaluation at 1-month intervals is beneficial for GISTs that are difficult to be diagnosed histopathologically.